Subclinical Atherosclerosis
Conditions
Interventions
Exposed group (leflunomide)
Control group (without leflunomide):None
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18 - 75 years old, gender unrestricted; 2. RA diagnosis: Confirmed as rheumatoid arthritis in accordance with the 2010 classification criteria of the American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR). 3. Disease activity: Patients with either active or stable disease are eligible, with a DAS28 score > 2.6 at the time of enrollment.
Exclusion criteria
Exclusion criteria: 1. Combine other severe rheumatic diseases: such as systemic lupus erythematosus, systemic sclerosis, dermatomyositis, etc. 2. Confirmed clinical cardiovascular diseases: History of definite myocardial infarction, unstable angina pectoris, coronary artery revascularization (stent or bypass); definite history of ischemic or hemorrhagic stroke; symptomatic peripheral artery disease; 3. Patients with previous high blood sugar and high blood lipids; at the time of enrollment, fasting blood glucose was >= 7.0 mmol/L and low-density lipoprotein was > 3.4 mmol/L; 4. History of drug use (which may interfere with the atherosclerotic process): Within 3 months prior to enrollment, use of glucocorticoids or non-steroidal anti-inflammatory drugs; within 3 months prior to enrollment, use of or being on any drugs known to significantly affect lipid metabolism or have clear vascular protective effects (statins, fibrates, high-dose fish oil, etc.);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in carotid intima-media thickness (CIMT) relative to the baseline at 12 months; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in the levels of serum TC, TG, HDL-C, LDL-C, blood glucose, insulin, IL-6, CRP, TNF-a.; | — |
Countries
China
Contacts
Public ContactFeng Tingting
Shanghai General Hospital
Outcome results
None listed